Sexually Transmitted Diseases

In this case study, clinicians review a challenging case.

NOWDiagnostics' represents a new option for early syphilis detection and aligns with ongoing efforts to improve STI screening.

The Public Health Agency of Sweden reported the individual sought care at Region Stockholm and has been diagnosed with mpox caused by clade I.

The vaccine, Jynneos, manufactured by Bavarian Nordic, is being shipped to Africa to address the ongoing mpox outbreak.

The federal agency says the ongoing outbreak of the clade 1 variant in the Democratic Republic of Congo has been reported in neighboring countries.

A pilot study looked at offering this form of pre-exposure prophylaxis (PrEP) to a select population to see if it could be effective in preventing sexually transmitted infections (STIs).

The WHO reports the variant, clade I MPXV, has been circulating in a region within the Democratic Republic of Congo since last year.

A continued clarion call is being sounded about the drug-resistant pathogen.

The federal agency gave the nod to Roche’s human papillomavirus (HPV) self-collection and gives women the ability to gather their own sample in a health care setting, which can then be sent off for lab results.

Here is an update on the latest research and clinical management.

April marks STI Awareness Month; guidelines decreasing the incidence of chlamydia and syphilis, future work needing to be done with regards to doxy-PEP, an increase in STIs during the pandemic, and more from this year by Contagion.

Both the use of a vaginal ring or oral pre-exposure prophylaxis were found to be safe for HIV prevention throughout pregnancy.

Biomarkers associated with mortality differed by sex and there may be distinct pathophysiologic mechanisms that account for the increased risk seen in females, according to investigators.

Promising oral antibiotic candidate for the treatment of uncomplicated urogenital gonorrhea

New review article outlines the evidence and future work that needs to be done with regards to doxycycline post-exposure prophylaxis (doxy-PEP).

Investigators recently noted that despite a decrease in adolescent hospital visits during the height of the pandemic, there was an increase in sexually transmitted infections (STIs) in this population group.

The latest data on sexually transmitted infections (STI) shows a large increase in syphilis incidence rates year-over year, where others were either flat or saw a slight decrease. The report also shows an ongoing rise of syphilis cases over the long-term.

New challenges in the fight against gonorrhea in the US.

Doxycycline postexposure prophylaxis (PEP) has reduced STIs among men who have sex with men, but poor adherence marred trial results with women.

A new study warns an increase in costs could lead to new infections.

Early treatment of the antiviral tecovirimat (TPOXX) could inhibit virus replication by more than 90%.

With an increased incidence of this sexually transmitted infection, a review of an older antibiotic for treatment has shown some clinical benefits in other countries.

The vaccine has been approved since late 2019 for adults age 18 and older.

The phase 1/2 trial evaluating EBT-101 dosed its first patient in September 2022.

The update refreshes the organization's 2022 guidance on HIV, viral hepatitis, and STI prevention, diagnosis, treatment, and care for key populations, focusing on people in prisons and other closed settings.

When taken within 3 days, doxycycline given post-exposure (doxy-PEP) decreased the incidence rates of syphilis, gonorrhea, and chlamydia significantly.

February 7 is National Black HIV/AIDS Awareness Day (#NBHAAD). In observance, we're recapping stories to raise awareness and work toward ending HIV/AIDS disparities in Black communities.

Sexually transmitted infections (STIs) received little attention during the pandemic, but the truth is the STIs did not stop infection increases shortly after the quarantine.

Genital herpes (HSV-2) affects quality-of-life but also causes substantial economic losses, especially in low- and middle-income countries.

HIV PrEP prescriptions increased from 0 among people who use injection drugs, but overall PrEP uptake remains low.